ACS management module 2: dual antiplatelet therapy

Released19 September 2017     Expires: 19 September 2019      Programme: ACS management 0.5 CPD/CME credits

Sponsorship Statement: AstraZeneca provided an arms-length grant to fund production of the supplement, on which this learning programme is based. AstraZeneca had no editorial input into the content other than a review for technical accuracy.

Designed to give healthcare professionals an understanding of dual antiplatelet therapy in the post-acute coronary syndrome patient, the different antiplatelet agents available and the optimal duration of therapy, with reference to balancing the risks of ischaemic and bleeding events in practice.

Learning objectives

Upon completing this module, participants should have a better understanding of:

  • the mechanisms of thrombus formation in the coronary artery
  • use of dual antiplatelet therapy with clopidogrel, prasugrel and ticagrelor in post-acute coronary syndrome management
  • use of dual antiplatelet therapy beyond one year
  • use of shorter antiplatelet therapy (three to six months)
  • use of ticagrelor-based prolonged dual antiplatelet therapy in selected high risk in patients with myocardial infarction and other high-risk features


Dr Wael Sumaya, BHF Clinical Research Training Fellow, University of Sheffield
Professor Robert F Storey, Professor of Cardiology, University of Sheffield; Academic Director, Sheffield Teaching Hospitals NHS Foundation Trust; Director, Cardiovascular Research Unit, Northern General Hospital, Sheffield

With thanks to Dr Kevin Cheng, Core Medical Trainee, London, for assistance on the self-assessment aspect of the programme


0.5 CPD/CME credit, 0.5 hours
BJC Learning has assigned half an hour of CPD/CME credit to this module

You need to login to take this module

You need to be a registered member to view this page. It's quick, free and offers you a host of other benefits, including the facility to print and download articles and supplements, access our archived issues and receive email updates when new issues and other content are online.

56 thoughts on “ACS management module 2: dual antiplatelet therapy”

All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.